Weiss Asset Management LP Acquires Shares of 36,954 Moderna, Inc. (NASDAQ:MRNA)

Weiss Asset Management LP acquired a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 36,954 shares of the company's stock, valued at approximately $2,470,000.

Other large investors have also bought and sold shares of the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna during the second quarter worth about $26,000. Family Firm Inc. bought a new stake in Moderna in the 2nd quarter valued at approximately $33,000. Hanseatic Management Services Inc. acquired a new position in Moderna during the 2nd quarter worth approximately $48,000. Plato Investment Management Ltd grew its stake in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after acquiring an additional 288 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of Moderna by 1,753.1% in the second quarter. Larson Financial Group LLC now owns 593 shares of the company's stock valued at $70,000 after purchasing an additional 561 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 715 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,850 shares of company stock valued at $134,560. 15.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on MRNA shares. Jefferies Financial Group lowered their target price on Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 price target for the company in a research note on Monday, November 18th. TD Cowen dropped their price objective on Moderna from $70.00 to $60.00 and set a "hold" rating on the stock in a research note on Friday, September 13th. The Goldman Sachs Group decreased their target price on shares of Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a research note on Monday, September 16th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research report on Friday, November 8th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $83.33.

Moderna Price Performance

NASDAQ:MRNA traded up $1.50 on Friday, hitting $44.44. The company had a trading volume of 8,735,641 shares, compared to its average volume of 10,344,880. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $17.10 billion, a price-to-earnings ratio of -7.64 and a beta of 1.58. The firm has a 50 day moving average of $50.27 and a two-hundred day moving average of $87.86.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the company earned ($1.39) earnings per share. On average, research analysts anticipate that Moderna, Inc. will post -9.32 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.